Mark S. Litwin, MD

Mark Litwin, MD, MPH


Professor, Department of Urology, UCLA Fielding School of Public Health, Department of Health Policy and Management, School of Nursing
Chair, Department of Urology
Director, Testicular Cancer Program, Institute of Urologic Oncology





Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica



Public Health/Public Policy, UCLA Fielding School of Public Health, 1991 - 1993


Surgery, Brigham and Women's Hospital, 1985 - 1987


MD, Emory University School of Medicine, 1985


Urology, Brigham and Women's Hospital, 1987 - 1991

Board Certification

Urology, American Board of Urology, 1995

Contact Information


(310) 794-7700 - Urology and Urologic Oncology information and referral

Clinical Interests

Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Robotic Prostatectomy, Testicular Cancer, Urinary Diversion

Scientific Interests

Dr. Mark S. Litwin devotes his time to surgical care and research for patients with urologic cancers. His research activity focuses on quality of care and medical outcomes assessment, health-related quality of life, medical decision-making and prostate cancer in the underserved. He has published numerous quality-of-care and quality-of-life measures, including the UCLA Prostate Cancer Index. He has also published extensively on quality of care in patients with prostate, bladder and kidney cancer. His research has been continuously funded by the National Institutes of Health since 1997. He has also received grants from the American Cancer Society, US Department of Defense, California Department of Public Health and other organizations.

Litwin directs IMPACT (, a $94-million program for low-income, uninsured Californians with prostate cancer. He was also the principal investigator of Urologic Diseases in America (, a recently completed $14-million NIH project quantifying the burden of urologic diseases on the American public. His former fellows serve in academic positions throughout the world.

Highlighted Publications

Filson CP, Marks LS, Litwin MS. Expectant management for men with early stage prostate cancer. CA Cancer J Clin. 2015 Jul-Aug;65(4):265-82. doi: 10.3322/caac.21278. Epub 2015 May 8.

Daskivich TJ, Kwan L, Dash A, Saigal C, Litwin MS. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer. J Urol. 2015 Jul;194(1):73-8. doi: 10.1016/j.juro.2015.01.081. Epub 2015 Jan 23.

Tan HJ, Filson CP, Litwin MS. Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer. Urol Oncol. 2015 Jan;33(1):21.e19-26. doi: 10.1016/j.urolonc.2014.10.002. Epub 2014 Nov 6.

Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, Litwin MS; Urologic Diseases in America Project. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011 Dec 1;117(23):5392-401. doi: 10.1002/cncr.26198. Epub 2011 Jul 11.

Chamie K, Connor SE, Maliski SL, Fink A, Kwan L, Litwin MS. Prostate cancer survivorship: lessons from caring for the uninsured. Urol Oncol. 2012 Jan-Feb;30(1):102-8. doi: 10.1016/j.urolonc.2011.09.001. Epub 2011 Nov 27.